Choose the Right Colon Cancer Screening Option

TUESDAY, March 26, 2019 — Colon cancer is highly preventable through regular screening. But the right type of screening depends on your particular risk factors, an expert says. Each year in the United States, more than 140,000 people are diagnosed with colon cancer, and about 50,000 die from the disease. It’s the second-leading cause of […]

Continue Reading

BridgIT, a new tool for orphan and novel enzyme reactions

Effective protein engineering can give us control over the generated products inside a cell. However, for many of the biochemical reactions responsible for these products, we don’t we don’t know the specific protein- or enzyme-producing gene responsible. These reactions are called “orphan” and have become a big problem for protein engineers. Moreover, software that predicts […]

Continue Reading

Boehringer Ingelheim announces FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILD

Boehringer Ingelheim has filed for regulatory approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) with the FDA and EMA. Nintedanib as an anti-fibrotic medicine is already approved in more than 70 countries for the treatment of patients living with idiopathic pulmonary fibrosis (IPF). Systemic sclerosis, also known as scleroderma, is […]

Continue Reading